Analysis of the Mechanism of Huatan Tongluo Formula (HTTLF) Combined with Western Medicine in the Treatment of Chronic Heart Failure Complicated with Depression Based on Molecular Docking and Co-Precipitation Technology

Abstract

Aim: In order to clarify the efficacy and mechanism of Huatan Tongluo Formula (HTTLF) combined with western medicine in the treatment of chronic heart failure complicated with depression. Methods: This study selected 120 patients with chronic heart failure and depression who were treated in our hospital from June 2019 to December 2021. The patients were randomly divided into 2 groups. Among them, 60 patients in the control group received conventional western medicine treatment, and 60 patients in the observation group were treated with HTTLF on the basis of conventional western medicine treatment. The clinical efficacy, quality of life, depression, biochemical indicators, and safety indicators of the two groups were compared, and the drug targets of the HTTLF were analyzed and verified by molecular docking and co-precipitation techniques. Results: The results showed that the combination of HTTLF and western medicine could significantly improve the symptoms and signs of disease model animals. Molecular docking and co-precipitation experiments showed that isorhamnetin, as the main component of HTTLF, targets the expression of MMP-9. After treatment, the depression self-rating scale score in the observation group was significantly lower than that in the control group, and the quality-of-life score was higher than that in the control group. Conclusions: HTTLF can target MMP-9 through monomer isorhamnetin, and combined with western medicine can significantly improve the therapeutic effect of chronic heart failure complicated with depression.